Rethinking neoadjuvant chemotherapy for breast cancer | The BMJ
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
Breast cancer recurrence: factors impacting occurrence and survival | Irish Journal of Medical Science (1971 -)
Adjuvant Chemotherapy Improves Prostate Cancer Survival - NCI
CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2− breast cancer: A meta‐analysis of randomized controlled trials - Wang - 2020 - The Breast Journal - Wiley Online Library
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Metastatic Breast Cancer
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status of adjuvant endocrine therapy for breast cancer | Breast Cancer Research | Full Text
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia | Scientific Reports
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Abemaciclib plus aromatase inhibitor in advanced breast cancer
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial | npj Breast Cancer
Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older - Trevor Jolly, Grant R Williams, Ellen Jones, Hyman B Muss, 2012
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial - The Lancet Oncology
Frontiers | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred | Scientific Reports
Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer | Chinese Medical Journal
Updates in endocrine therapy for metastatic breast cancer | Cancer Biology & Medicine
Chemotherapy Statistics | Success Rate & Cost
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy | Breast Cancer Research | Full Text
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
BREAST CANCER - Daily Reporter
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
